Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Erro Iribarren (Madrid, Spain), C. Cisneros Serrano (Madrid, Spain), C. Acosta Gutiérrez (Madrid, Spain), A. Roca Noval (Madrid, Spain), A. Martínez Meca (Madrid, Spain), E. García Castillo (Madrid, Spain), M. Hernández Olivo (Madrid, Spain), J. B Soriano (Madrid, Spain), J. Ancochea Bermúdez (Madrid, Spain). Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma. 2520

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021